PDCD1 and cancer: Immune checkpoint inhibitors, such as monoclonal antibodies targeting the PD-1/PD-L1 axis and CTLA-4, have significantly improved the efficacy of cancer therapy, and the development of this type of tools has emerged as one of most active field of research (1–3).